Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast15
2023-505616-38-00Phase 2Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Time to next treatment. Planned start Dec 2023; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-505616-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505616-38-00.